San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Perfuse Therapeutics is raising $38,999,964.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Sevgi Gurkan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Perfuse Therapeutics

Perfuse Therapeutics is a seed-stage company pursuing a novel mechanism to improve retinal perfusion in the context of various retinal diseases, starting with glaucoma. Perfuse Therapeutics is pursuing a novel mechanism to treat various eye diseases, starting with glaucoma, by improving retinal perfusion.

To learn more about Perfuse Therapeutics, visit http://perfusetherapeutics.com/

Contact:
Sevgi Gurkan, Chief Executive Officer
415-272-1083
https://www.linkedin.com/in/sevgi-gurkan-md-95b7145/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved